Immuron Ltd — Board/Management Information 2015

Jul 7, 2015

==> picture [194 x 55] intentionally omitted <==

RESIGNATION OF CHIEF EXECUTIVE OFFICE (CEO)

8 July 2015, Melbourne, Australia: The Board of Immuron has today announced that it has received a notice of resignation from the Company’s Chief Executive Officer (CEO) Dr Leearne Hinch.

While the resignation will be effective today, Dr Hinch has agreed to remain with the Company as a consultant until the end of the month to facilitate a smooth transition to new management and undertake a comprehensive handover.

The Company announced in May the appointment of Mr Peter Anastasiou as a Non-Executive Director, and in June the appointment of Dr Dan Ruben Peres as Senior Vice President of Innovation. With these two earlier appointments the Board is confident it will have the short term coverage until a new CEO can be appointed whilst ensuring continued steady growth of Travelan, and the ongoing progression of the NASH and ASH trials as planned.

Non-Executive Chairman, Dr Roger Aston said:

“The Board wishes Leearne success in her future career. The Company will now seek to recruit a new Chief Executive Officer whose primary focus will be to expand the Company’s flagship product Travelan into a truly globally available product and explore other new synergistic technologies in the hyperimmune colostrum space, whilst Dr. Peres drives the clinical trials forward.”

Immuron is also currently recruiting for two other key management positions to strengthen the management team and lead the company forward.

Contacts:

Dr Roger Aston Dr Dan Peres Non-Executive Chairman Senior VP of Innovation +61 (0) 402 762 204 +972 545 641 464

Amanda Loh Buchan Consulting +61 (0)3 9866 4722

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapies based on its hyperimmune colostrum technology for the treatment of intestinal and liver diseases. The company currently markets Travelan® for the prevention of travellers’ diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735